

Elinor Cecile Gray Chumney, Ph.D., M.Sc.
Assistant Dean of Student Affairs
Associate Professor
Belmont University School of Pharmacy
Gordon E. Inman College of Health Sciences and Nursing
1900 Belmont Boulevard
Nashville, Tennessee 37212-3757

Phone (615)460-6810 and Fax (615) 460-6741
Email: chumneye@mail.belmont.edu

EDUCATION

- 1991-1995 Davidson College, Davidson, NC
Bachelor of Arts - Economics (minor in Medical Humanities)
- 1996-1998 University of York, York, England
Masters of Science - Health Economics
- 1998-2002 University of North Carolina School of Public Health - Chapel Hill, NC
Doctor of Philosophy - Department of Health Policy and Administration

RESEARCH APPOINTMENTS

- 1994 Research Assistant
Department of Orthopedics
Carolina's Medical Center
Charlotte, NC
- 1995-1996 Research Assistant
Department of Health Care Services
Institute of Medicine (IOM)
National Academy of Sciences
Washington, DC
- 1997 Research Associate
Department of Analysis and Research Assessment
World Health Organization (WHO)
Geneva, Switzerland
- 1998 Research Assistant
Office of the Chief of Staff
University of Virginia Health Sciences Center
Charlottesville, VA

RESEARCH APPOINTMENTS (continued)

- 1999-2001 Research Assistant
Department of Health Policy and Administration
University of North Carolina at Chapel Hill
Chapel Hill, NC
- 2000 Consultant on Economic Analyses
Center for Health Care Research
Medical University of South Carolina
Charleston, SC
- 2001 Statistical Analyst and Senior Research Associate
Center for Health Care Research
Medical University of South Carolina
Charleston, SC

ACADEMIC APPOINTMENTS

- 1999 Teaching Assistant
Department of Health Policy and Administration
University of North Carolina at Chapel Hill
Chapel Hill, NC
- 2000 Visiting Lecturer
College of Pharmacy
Medical University of South Carolina
Charleston, SC
- 2001-2002 Instructor
Department of Pharmacy Practice
College of Pharmacy
Medical University of South Carolina
Charleston, SC
- 2003-2007 Assistant Professor
Department of Pharmacy and Clinical Sciences
South Carolina College of Pharmacy
(formerly Medical University of South Carolina College of Pharmacy)
Charleston, SC
- 2005-2007 Dual appointment, Assistant Professor
Department of Health Administration and Policy
College of Health Professions
Medical University of South Carolina
Charleston, SC

ACADEMIC APPOINTMENTS (continued)

2007-present Assistant Dean of Student Affairs
Associate Professor
Belmont University School of Pharmacy
Gordon E. Inman College of Health Sciences and Nursing
Nashville, TN

HONORS AND AWARDS

1996-1997 Rotary Ambassadorial Scholarship
1999-2000 University of North Carolina Graduate School Merit Assistantship
2000-2001 Public Health Service Traineeship Award
2003-2004 MUSC Student Government Association's Student Choice Award for Innovation and Pharmacy Education
2006 Most Outstanding Abstract, ISPOR 11th Annual International Meeting

SECTION I: SERVICE

University Service

2007-present SOP Representative, Belmont's Mission Committee
2007-2007 SCCP Representative, Teaching Excellence Awards Review Committee
2006-2007 SCCP Representative, MUSC Faculty Senate
2005-2007 SCCP Representative, NIH T32 Training Grant Steering Committee
2005-2007 Member, MUSC Women Scholars Initiative
2004-2007 Member, MUSC Graduate Faculty
2003-2007 Member, MUSC's Center for Health Economic and Policy Studies
2003-2007 SCCP Representative, Apple Tree Steering Committee
2002-2007 Member, MUSC's Waring Library Historical Society

College and Department Service

2006-2007	Member, SCCP Student Grievance Committee
2004-2007	Director, MUSC's Dual PharmD/MBA Degree Program
2003-2007	Class Advisor, MUSC's Doctor of Pharmacy Class of 2007
2003-2004	Member, MUSC's PLS Leadership Seminar Series Planning Committee
2003	Member, MUSC's Drug Information Faculty Search Committee
2003-2007	Member, MUSC's Information Technology Committee
2003-2007	Member, MUSC's Student Activities Committee
2003-2004	Chairman, MUSC's Joint PharmD/MBA Program Working Group
2001-2003	Coordinator, MUSC's Dean's Seminar Series
2001-2007	Regularly interview and rank prospective students
2001-2004	Member, MUSC's Research and Graduate Studies Committee

Professional Affiliations and Service

2001-present	Member, International Society for Pharmacoeconomics and Outcomes Research
2004-present	Member, Communications Task Force
2003-2005	Chairman, Research Network Working Group
2002-2005	Member, Managed Care/Pharmacy Benefit Special Interest Group
2002-2003	Chairman, Pharmacoeconomic Language Subcommittee
2005	Member, Health Technology Assessment Special Interest Group
2001-present	Member, Academy for Health Services Research and Health Policy
2002-present	Member, International Health Economics Association
2002-present	Member, American Association of Colleges of Pharmacy
2005	Faculty Delegate to AACP Annual Meeting
2006	Faculty Delegate to AACP Annual Meeting

Professional Affiliations and Service

- 2003-2004 Member, American Pharmaceutical Association
- 2004-present Member, American Society of Health Economists
- 2005-present Reviewer, *Health Policy*
- 2005-present Reviewer, *Journal of the National Medical Association*
- 2006-present Reviewer, *Pharmacoeconomics*
- 2008-present Member, Tennessee Pharmacist Association

Mentoring Activities

- 2005-2006 Doctoral Dissertation Committee Member for Maghram Alamri, MUSC's Department of Health Administration and Policy.
- 2004-2006 Doctoral Dissertation Committee for Russell Goodman, MUSC's Department of Biometry and Epidemiology.
- 2004-2007 Doctoral Dissertation Committee Member for Shayna Lunsford, MUSC's Department of Biometry and Epidemiology.
- 2003-2007 Class Advisor for all 80 Doctor of Pharmacy students in MUSC's Class of 2007
- 2002-2007 Faculty Advisor to 12 other MUSC and SCCP Doctor of Pharmacy students
- 2004-2005 Mentor for Pamela Mazyck, PharmD, Assistant Professor at MUSC
- 2004-2006 Mentor for three undergraduate EXPORT students during internship at MUSC
- 2003-2004 Mentor for Jennifer Mazyck-Brown, PharmD, Research Fellow at MUSC

SECTION II: SCHOLARSHIP

Books

The Effect of Various Costing Approaches on the Resulting Cost-effectiveness Ratios and the Policy Significance of these Variations (Doctoral dissertation, University of North Carolina at Chapel Hill). Dissertation Abstracts International, 63, 5181 (2002).

Methods and Designs for Outcomes Research (Editor), American Society of Health-System Pharmacists (2005).

Book Chapters

1. Carrin G, **Gray E**, and Almeida, J. Coping with ill-health in a rickshaw puller's household in Chittagong, Bangladesh. Macroeconomics and Health Development Series. Geneva, Switzerland: World Health Organization 1998.
2. **Chumney ECG**. Introduction to Outcomes Research (Chapter 1). Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists 2005.
3. **Chumney ECG**. Ecologic Analysis (Chapter 3). Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists 2005.
4. **Chumney ECG** and Simpson K. Introduction to Regression Analyses (Chapter 8). Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists 2005.
5. Simpson K and **Chumney ECG**. Decision Models: Markov Models and Decision Trees (Chapter 12). Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists 2005.
6. **Chumney ECG** and Simpson K. Cost-utility Analyses (Chapter 15). Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists 2005.

Peer-reviewed Journal Articles

1. Carrin G, **Gray E**, and Almeida, J. Coping with ill-health in Bangladesh: A rickshaw puller's household. *Southeast Asian Journal of Tropical Medicine and Public Health* 1999. 30(1): 136-48.
2. Simpson KN, Voit EO, Goodman R, **Chumney ECG**. Estimating the social and economic benefits of pharmaceutical innovations: Modeling clinical trial results in HIV-disease. *Research in Human Capital and Development* 2001. 14: 175-198.
3. **Chumney ECG** and Simpson KN. The Emerging Role of the Consumer in Pharmaceutical Pricing Decisions. *Disease Management and Health Outcomes* 2002. 10(4): 229-232.
4. Simpson KN, Luo MP, **Chumney ECG**, et al. Cost-Effectiveness of Lopinavir/Ritonavir versus Nelfinavir as the First-line Highly Active Antiretroviral Therapy Regimen for HIV Infection. *HIV Clinical Trials* 2004. 5(5): 294-304.
5. **Chumney ECG**, Biddle AK, Simpson KN, et al. The Effect of Cost Construction Based on Either DRG or ICD-9 Codes or Risk Group Stratification on the Resulting Cost-Effectiveness Ratios. *Pharmacoeconomics* 2004. 22(18): 1209-16.

Peer-reviewed Journal Articles continued

6. Ragucci KR, Wessell A, Fermo JD, and **Chumney E**. Evaluation of the effectiveness of pharmacist-administered diabetes education and management services. *Pharmacotherapy* 2005. 25(12): 1809-1817.
7. **Chumney ECG** and Ragucci KR. Survey of student satisfaction and academic performance in a Dual PharmD/MBA Degree Program. *American Journal of Pharmaceutical Education* 2006. 70(2):26-29.
8. **Chumney EG**, Simpson KN, and Mauldin PD, et al. Charges for Hospital Admissions Attributable to Health Disparities for African American Patients in South Carolina During 1998-2002. *Journal of the National Medical Association* 2006. 98(5): 690-694.
9. Whitley HP, Fermo JD, and **Chumney ECG**. A 5-year evaluation of “flags” placed in the electronic medical record alerting clinicians to patients warranting secondary prevention of coronary heart disease. *Pharmacotherapy* 2006. 26(5): 682-688.
10. **Chumney ECG** and Robinson L. The effects of pharmacist interventions on patients with polypharmacy. *Pharmacy Practice* 2006. 4(3):103-109.
11. **Chumney ECG**, Dismuke L, and Marques RG. Medical Evidence Regarding the Controversy over Alcoholic Liver Disease Transplantation. *The Journal of the South Carolina Medical Association* 2006. 98(5):690-94.
12. Whitley H, Fermo J, Ragucci K, and **Chumney ECG**. Assessment of patient knowledge of diabetic goals, self-reported medication adherence, and goal attainment. *Pharmacy Practice* 2006. 4(4):183-190.
13. Simpson KN, Luo MP, **Chumney ECG**, King MS, and Brun S. Cost-effectiveness of lopinavir/ritonavir compared to atazanavir in antiretroviral-naïve patients: Modeling the combined effects of HIV and heart disease. *Clinical Drug Investigation* 2007. 27(1):67-74.
14. Whitley H, Fermo J, **Chumney ECG**, and Brzezinski W. Effect of patient-specific factors on weekly warfarin dose. *Therapeutics and Clinical Risk Management* 2007. 3(3): 499-504.
15. Wiest D, **Chumney ECG**, and Nappi J. Pre-admission Predictors of Graduating Grade Point Average in a Professional Pharmacy Program. *Journal of Pharmacy Technology* 2008 (accepted, publication pending).
16. **Chumney ECG**, Ragucci K, and Jones K. What difference does a PharmD/MBA make? *American Journal of Pharmacy Education* 2008 (accepted, publication set for April 15, 2008).
17. Jennings D, Ragucci K, **Chumney E**, and Wessell A. Impact of clinical pharmacist intervention on diabetes related quality-of-life in an ambulatory care clinic. *Pharmacy Practice* 2007. 5(4):169-173.

Peer-reviewed Journal Articles continued

18. Garin MC, **Chumney ECG**, Simpson KN, and Highland KB. Cost-utility of Treatments for Pulmonary Arterial Hypertension. Submitted to Chest.

Other Journal Articles

1. **Chumney ECG**, Biddle AK, Simpson KN, et al. Survey of Acceptable Variations in Cost-effectiveness Ratios: A Brief Overview. *ISPOR Connections* 2003. 9(5): 13-14.
2. **Chumney ECG**, Delinokov S, Fuldeore M, et al. What exactly do you mean by that? A Summary of Discrepancies in the Definitions of Key Pharmacoeconomic and Outcomes Research Terms: A White Paper. *ISPOR Connections* 2004. 9(1): 6-7.
3. **Chumney ECG**. Let's Get Talking: New Initiatives for Facilitate Communication among ISPOR Researchers. *ISPOR Connections* 2004. 10(5): 10-11.
4. **Chumney ECG** and Simpson KN. Calculating study power for economic analyses alongside clinical trials. *ISPOR Connections* 2006. 12(6): 8-10.

Published Abstracts

1. "Estimated Five-year Budget Impact and Median Lifetime Cost Utility Ratio for Treatment-Naïve Patients Started with Kaletra vs a Nelfinavir Containing Regimen: Estimates for SC Medicaid Health Disparity Areas. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting. September 2001.
2. "Effect of Patient Counseling on Dispensing Errors in a Community Pharmacy." Proceedings of the American Pharmaceutical Association (APhA) Annual Meeting and Exposition in Philadelphia, PA. March 2002.
3. "Loss of SSRI Effectiveness During Continuation or Maintenance Therapy of Major Depression." Proceedings of the College of Psychiatric and Neurologic Pharmacists Meeting in Seattle, WA. April 2002.
4. "The Potential Effect of Data Sources and Analytic Approaches to the External Validity of Economic Studies." Proceedings of the Annual International Society for Pharmacoeconomics and Outcomes Research Meeting in Washington, DC. May 2002.
5. "Disparities in the Cost of HIV Disease Treatment by Race." Proceedings of the AcademyHealth's Annual Research Meeting in Washington, DC. June 2002.
6. "Cost Effectiveness of using Lopinavir/Ritonavir vs. Nelfinavir as the First Highly Active Antiretroviral Therapy Regimen for HIV Infection." Presented in Glasgow, Scotland. July 2002.

Published Abstracts continued

7. "Five Year Budget Impact and Lifetime Cost Effectiveness of a Lopinavir (Kaletra) vs. a Nelfinavir (NLF) Containing Regimen for Treatment-naïve Patients." Proceedings of the Interscience Conference on Anti-microbial Agents and Chemotherapy Meeting in San Diego, CA. September 2002.
8. "The implementation and evaluation of smart infusion pump technology to determine the potential for reducing medication errors in the medical/surgical intensive care unit." Proceedings of the University Health Consortium Pharmacy Council Meeting in New Orleans, LA. December 2003.
9. "Expected quality of life and cost implications of R-CHOP and radioimmunotherapy regimens for indolent non-hodgkins lymphoma." Proceedings of the American Pharmaceutical Association Annual Meeting and Exposition in Seattle, WA. March 2004.
10. "Cost of hospital admissions attributable to minority health disparities in South Carolina." Proceedings of the AcademyHealth's Annual Research Meeting in San Diego, CA. June 2004.
11. "Cost effectiveness of Lopinavir vs Atanavir in treating antiretroviral-naïve patients: Modeling the combined effects of HIV and heart disease." Proceedings of the 7th International Congress on HIV Infection in Glasgow, Scotland. November 2004.
12. "Medication Information Needs in Community-based Older Patients: A Pilot Survey." Proceedings of the 2nd Annual Aging Research Day in Columbia, SC. April 2005.
13. "An Evaluation of the Dual PharmD/MBA Degree Program between the Medical University of South Carolina's College of Pharmacy and The Citadel's School of Business Administration." Proceedings of the Charleston Connections 2005 Innovations in Higher Education Conference in Charleston, SC. May 2005.
14. "An Evaluation of Applicant Interview Scores and Letters of Reference in Predicting Student Success." Proceedings of the Charleston Connections 2005 Innovations in Higher Education Conference in Charleston, SC. May 2005.
15. "The Pharmacy College Admission Test (PCAT) vs the Student Aptitude Test (SAT) in Predicting Pharmacy Student Academic Success." Proceedings of the American Association of Colleges of Pharmacy (AACCP) Annual Meeting in Cincinnati, OH. July 2005.
16. "An Evaluation of the Dual PharmD/MBA Degree Program between the Medical University of South Carolina's College of Pharmacy and The Citadel's School of Business Administration." Proceedings of the AACCP Annual Meeting in Cincinnati, OH. July 2005.
17. "An Evaluation of Applicant Interview Scores and Letters of Reference in Predicting Student Success." Proceedings of the AACCP Annual Meeting in Cincinnati, OH. July 2005.

Published Abstracts continued

18. "Combivir vs. Generic Zidovudine and Epivir: An Economic Modeling Study." Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil. July 2005.
19. "Charges for Hospital Admissions Attributable to Health Disparities for African American Patients in South Carolina during 1998-2002." Proceedings of the ISPOR 8th Annual European Congress in Florence, Italy. November 2005.
20. "Quality assurance analysis and identification of risk factors for inadequate response to erythropoietin replacement therapy in chronic kidney disease." American College of Clinical Pharmacy Annual (ACCP) Meeting in San Francisco, CA. December 2005.
21. "Effect of patient-specific factors on weekly warfarin dose." American Society of Health-System Pharmacists Midyear in Las Vegas, NV. December 2005.
22. "Correlation of patients' understanding of diabetic goals and goal attainment." University Health Consortium Pharmacy Council Meeting in Las Vegas, NV. December 2005.
23. "Correlation of warfarin dose and patient-specific characteristics." University Health Consortium Pharmacy Council Meeting in Las Vegas, NV. December 2005.
24. "Quality assurance and identification of risk factors for inadequate response to erythropoietin replacement therapy in chronic kidney disease." ACCP Spring Practice and Research Forum in Monterey, CA. April 2006.
25. "Cost effectiveness of tipranivir in treatment-experienced HIV patients in the USA." ISPOR 11th Annual International Meeting in Philadelphia, PA. May 2006.
26. "Development and Initiation of a Peer Evaluation Process for Classroom Teaching." AACP Annual Meeting in San Diego, CA. July 2006.
27. "Impact of a Hospital-acquired/Ventilator-associated/Healthcare-associated Pneumonia Practice Guideline on Outcomes in Surgical Trauma Patients." ACCP Spring Practice and Research Forum in Memphis, TN. April 2007.
28. "Assessment of a Peer Evaluation Process for Classroom Teaching." Proceedings of the Charleston Connections 2007 Innovations in Higher Education Conference in Charleston, SC. May 2007.
29. "Diabetes related quality of life in an ambulatory care clinic." ACCP Annual Meeting in Denver, CO. October 14-17, 2007.

Complete WebCT Courses Developed

Designs for Outcomes Research (PHMPR-709)

Statistical Analysis for Health Systems (HAP-725-1)

Statistical Analysis for Health Systems (HAP-725-2) for distance education students

Statistics for Outcomes Research (PHMPR-751)

Extramural Grants

- 2007-2009 Veterans Affairs Health Services Research and Development Career Development Award (CDA). *Pharmacist Interventions for Diabetes Care in the VA*. Principal Investigator. Total direct costs: \$300,000 (Not funded).
- 2006-2008 Department of Defense. *Public Health and Economic Implications of Free Nicotine Replacement*. Co-Principal Investigator. Total direct costs: \$289,221 (Funding 30% of salary).
- 2002-2006 Boehringer Ingelheim Pharmaceuticals, Inc. *Economic and Quality of Life Component for the Phase III Clinical Trials of Tipranavir*. Co-investigator. Total direct costs: \$198,270 (Funding 10% of salary).
- 2000-2005 Agency for Healthcare Research and Quality. *Understanding and Eliminating Minority Health Disparities in Blacks*. Co-investigator. Total direct costs: \$1,600,100 (Funding 23% of salary).
- 2003-2005 Abbott Laboratories, Pharmaceutical Products Division. *Pharmacoeconomic Model of Kaletra and Atazanavir in treating antiretroviral naïve HIV patients*. Investigator. Total direct costs: \$88,500 (Funding 7% of salary).
- 2004-2005 GlaxoSmithKline, Pharmaceutical Products Division. *Cost-effectiveness Modeling for Fixed Dose Combination Products*. Co-investigator. Total direct costs: \$69,250 (Funding 18% of salary).
- 2004 National Community Pharmacists Association. *Blueprint for developing future pharmacy owners in the classroom*. Principal Investigator. Total direct costs: \$49,480 (not funded).
- 2004 Agency for Healthcare Research and Quality Small Grant Research Program. *Modeling Selection Bias: Racial Differences in Outcomes*. Principal Investigator. Total direct costs: \$67,960 (not funded).

2005 National Cancer Institute/Agency for Healthcare Research and Quality. *Selection Bias: Racial Differences in Digestive Cancers*. Total direct costs of \$100,000. Co-Investigator (not funded).

Extramural Grants continued

2003-2004 National Development and Research Institute. *Women's Prison Total Cost: Outcomes, Process, and Economic Analysis*. Investigator. Total direct costs: \$25,400.

2003 Medicaid Contracts proposal. *Effects of Chronic Use of Gastric Acid Suppressant Agents and Iron-deficiency Anemia on Resource use in the Medicaid population*. Principal Investigator (not funded).

2003 Medicaid Contracts proposal. *Effects of Inhaled Corticosteroids on Resource Use by Medicaid Patients with Chronic Obstructive Pulmonary Disease*. Investigator (not funded).

2002-2003 Agency for Healthcare Research and Quality HS-00-003. Program Grant for Understanding and Eliminating Health Disparities. *Economic Access to Antiretroviral Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina*. Co-investigator.

2000-2002 Department of Defense/Hollings Cancer Center. *Pilot Study for Standardized Indicators of Cancer Control Impact*. Co-investigator.

2000-2002 Abbott Laboratories, Pharmaceutical Products Division. *ABT-378 Cost-Effectiveness Model-Phase II*. Co-investigator.

2001 Boehringer Ingelheim Pharmaceuticals, Inc. *Design and analysis of quality of life and cost data in Phase III pivotal studies of drugs in patients who have failed two or more antiretroviral drug regimens containing protease inhibitors*. Investigator.

2000-2001 Verdict Center for Excellence. Co-investigator.

SECTION III: TEACHING

Courses Taught

1. Guest lecturer for June 7, 2007. "Decision Analysis using Markov Models"
2. Guest lecturer for Advanced Drug Information (PHMPR 729) March 21-23, 2007. "Critical Literature Evaluation" and "Statistics."

3. Course coordinator for Statistics for Outcomes Research (PHMPR-751). Elective course covering statistics and regression within the context of pharmacoeconomic analyses. Spring 2005, 2006, and 2007.

Courses Taught continued

4. Course coordinator for Statistical Analysis for Health Systems (HAP-725, Section 01). Required course covering statistical analysis for residential MHA students. Fall 2005.
5. Course coordinator for Introduction to Decision Analysis (BMTRY 732). Required course covering outcomes research methods for distance education students with the Institute for Research Minority Training on Mental Health and Aging (IRMMA) students. Fall 2005.
6. Course coordinator for Statistical Analysis for Health Systems (HAP-725, Section 02). Required course covering statistical analysis for executive (distance education) MHA students. Fall 2005.
7. Instructor for Operations Research and Decision Analysis (HAP 720). Required course covering outcomes research methods for executive (distance education) MHA students. Summer 2005.
8. Preceptor for PharmD Resident in Outcomes Research. August 2005.
9. Course coordinator for Designs for Outcomes Research II (PHMPR-751). Elective course covering study design, regression, modeling, and pharmacoeconomic analyses in detail. Spring 2004.
10. Course coordinator for Designs for Outcomes Research (PHMPR-709). Required course providing an introduction to study design, regression, modeling, and pharmacoeconomic analyses for third year PharmD students. Fall 2001, Fall 2002, Spring 2002, Spring 2003, Spring 2004, Spring 2005, Spring 2006, and Fall 2006.
11. Course coordinator for Rx Discount Card Programs (PHMPR-751). Elective course covering recently proposed health insurance and prescription discount plans in the United States. Spring 2002 and Summer 2003.
12. Course coordinator for the Department of Pharmaceutical Sciences Seminar Series (PHMSC 780). Required course for PhD students and open to all interested students. Spring 2001, Fall 2001, Spring 2002, Fall 2002, and Spring 2003.
13. Guest lecturer for HPAA 360 at the University of North Carolina at Chapel Hill's School of Public Health on September 27, 2001. "Costing Methods for HIV/AIDS."
14. Guest lecturer for Biometry 789 at MUSC on July 16, 2002. "Issues in Costing."

Invited Presentations and Workshops

1. “Managed Care and Pharmacy Benefit Management Special Interest Group Forum: Pharmacoeconomic Language.” Workshop for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 8th Annual International Meeting in Washington, DC on May 20, 2003.

Invited Presentations and Workshops continued

2. "Determining Costs for Cost-effectiveness Analyses." Digestive Disease Center's Seminar Series at the Medical University of South Carolina on October 23, 2003.
3. “Cost-effectiveness Ratios: Coding Sensitivity and Policy Significance.” Center for Health Economics and Policy Studies Seminar Series at the Medical University of South Carolina on November 21, 2003.
4. “Integrating Clinical Trial, Epidemiologic, and Cost Data.” International Symposium on Pharmacoeconomics in Lisbon, Portugal on April 15, 2005.
5. “Approaches to Estimating Maximum Study Power for Economic Endpoints in Fixed Sample Size Designs.” Workshop for the ISPOR 10th Annual International Meeting in Washington, DC on May 17, 2005.
6. “Calculating Study Power for Economic Analyses Alongside Clinical Trails.” Workshop for the ISPOR 8th Annual European Congress in Florence, Italy on November 8, 2005.
7. “Data Coding from Medical Records.” Workshop for MUSC residents on October 19, 2006.